Star said in a press release it is applying its expertise in rare diseases and antibody drug discovery to generate drug programs that target multiple diseases with a single therapy.

Star has raised over $100 million in financing since its inception in 2018 from Westlake Village BioPartners, OrbiMed, Redmile Group, Cormorant Asset Management, RA Capital, Cowen Healthcare Investments, and New Leaf Venture Partners.

Star Therapeutics is a biotechnology company whose mission is to develop life-changing therapies for the millions of patients who lack effective treatment options.

Why one industry veteran launched a new cancer immunotherapy company
WASHINGTON, DC - Raphaël Ognar spoke with ScienceBoard onsite at the Society for Immunotherapy of Cancer's 2021 annual meeting about the launch...